Welsh, F., Farmery, S., MacLennan, K., Sheridan, M., Barclay, G., Guillou, P., & Reynolds, J
TRIPLE GLUCAGON-LIKE PEPTIDE-1/GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE/GLUCAGON RECEPTOR TRIAGONISTS Undoubtedly, the approval of the first GLP-1 receptor agonist in 2005 has revolutionised the pharmacological treatment of obesity and T2DM
15 mg: the maximum dose The highest approved dose produces the greatest average weight loss, 22.5% in SURMOUNT-1, but the incremental benefit over 10 mg is modest
6 In a randomized, controlled, crossover study in healthy subjects, consuming 180 mg of curcumin before a carbohydrate-rich meal significantly reduced the incremental area under the curve for plasma glucose over 120 minutes by approximately 36 percent compared with control, without major adverse events